@article{ref1,
title="Relationships between cerebral flow velocities and neurodevelopmental outcomes in children with moderate to severe traumatic brain injury",
journal="Child's nervous system",
year="2018",
author="O'Brien, Nicole Fortier and Maa, Tensing and Moore-Clingenpeel, Melissa and Rosenberg, Nathan and Yeates, Keith Owen",
volume="34",
number="4",
pages="663-672",
abstract="PURPOSE: This study aimed to determine relationships between cerebral blood flow and neurodevelopmental outcomes in children with moderate to severe traumatic brain injury (TBI). <br><br>METHODS: Children with TBI, a Glasgow Coma Score of 8-12, and abnormal brain imaging were enrolled prospectively. Cerebral blood flow velocity (CBFV) was assessed within 24 h of trauma and daily thereafter through death, discharge, or hospital day 8, whichever came first. Twelve months from injury, participants completed neurodevelopmental testing. <br><br>RESULTS: Sixty-nine patients were enrolled. Low flow velocities (< 2 SD below age/gender normal) were found in 6% (n = 4). No patient with a single low CBFV measurement had a good neurologic outcome (Pediatric Glasgow Outcome Scale (GOS-E Peds) ≤ 4)). Normal flow velocities (± 2 SD around age/gender normal) were seen in 43% of participants (n = 30). High flow velocities (> 2 SD above age and gender normal with a Lindegaard ratio (LR) < 3) were identified in 23% of children (n = 16), and vasospasm (> 2 SD above age/gender normal with LR ≥ 3) was identified in 28% (n = 19). Children with good outcomes based on GOS-E Peds scoring were more likely to have had normal flow velocity than other flow patterns. No other differences in neurodevelopmental outcomes were noted. <br><br>CONCLUSIONS: Individual patient responses to TBI in terms of CBFV alterations were heterogeneous. Low flow was uniformly associated with a poor outcome. Patients with good outcomes were more likely to have normal flow. This suggests CBFV may serve as a prognostic indicator in children with TBI. Future studies are needed to determine if aberrant CBFVs are also a therapeutic target.<p /> <p>Language: en</p>",
language="en",
issn="0256-7040",
doi="10.1007/s00381-017-3693-6",
url="http://dx.doi.org/10.1007/s00381-017-3693-6"
}